RecruitingNCT06388967

Pancreatic Cancer Detection Consortium

Early Detection of Pancreatic Cancer: Prospective Study

Sponsor

City of Hope Medical Center

Enrollment

2,000 participants

Start Date

Mar 15, 2023

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer Pancreatic Carcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Adenocarcinoma Pancreatic Neoplasms Pancreatic Cancer, Adult Pancreatic Cancer Resectable Pancreatic Cancer Non-resectable Pancreatic Cancer Stage I Pancreatic Cancer Stage Pancreatic Cancer Stage 0 Pancreatic Cancer Stage II Pancreatic Cancer Stage III

Summary

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a large research database of blood and tissue samples from patients with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) to help develop better blood tests that can detect this cancer at an early, treatable stage. **You may be eligible if...** - You have been diagnosed with pancreatic ductal adenocarcinoma at any stage - You received standard diagnostic procedures and had at least one blood sample taken before any curative treatment, OR - You have been confirmed not to have pancreatic cancer (as a non-disease comparison group) **You may NOT be eligible if...** - You have not provided written informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPANcreatic cancer Exosome Early detectiON (PANXEON)

This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Locations(11)

Translational Genomics Research Institute

Phoenix, Arizona, United States

Honorhealth

Scottsdale, Arizona, United States

City of Hope Medical Center

Monrovia, California, United States

Hoag Center

Newport Beach, California, United States

OSF HealthCare

Peoria, Illinois, United States

Ochsner Medical Center

Jefferson, Louisiana, United States

Atlantic Health System

Morristown, New Jersey, United States

Piedmont Medical Center

Rock Hill, South Carolina, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Nagoya University

Nagoya, Japan

Asan Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06388967

Related Trials

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT0699589837 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

DESTINY-PANTUMOUR04

NCT0712400017 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121279 locations